TITLE

2008 - Review: D-dimer levels predict risk for recurrent VTE after anticoagulant therapy is stopped

AUTHOR(S)
Garcia, David A.
PUB. DATE
February 2009
SOURCE
ACP Journal Club;2/17/2009, Vol. 150 Issue 2, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a research conducted by researcher M. Verhovsek and colleagues on predicting risk by D-dimer levels for recurrent symptomatic venous thromboembolism (VTE) after anticoagulant therapy is stopped in patients. Studies selected measured D-dimer levels at 3 weeks to 2 months after stopping anticoagulant therapy in patients with a first unprovoked VTE who received therapy for 3 months.
ACCESSION #
36911248

 

Related Articles

  • Genotype-guided warfarin dosing now a reality. Cooper-DeHoff, Rhonda M.; Pacanowski, Michael A. // Cardiology Today;Feb2008, Vol. 11 Issue 2, p18 

    The article provides information on the use of the drug warfarin. It states that the drug is the most commonly prescribed oral anticoagulant and is effective for treating thromboembolism and stroke. It is noted that optimal warfarin dosage is difficult because of its narrow therapeutic index and...

  • Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects. Schulman, Sam // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p21 

    This article focuses on a study related to comparing self-management of oral anticoagulant therapy with clinic management. Patient self-management of oral anticoagulants resulted in similar levels of control and major bleeding and lower rates of arterial thromboembolism and death than...

  • Choosing a Parenteral Anticoagulant Agent. Diuguid, David L. // New England Journal of Medicine;11/1/2001, Vol. 345 Issue 18, p1340 

    Editorial. Discusses how to choose an anticoagulant agent for the treatment of and prophylaxis against arterial and venous thromboembolic disease. Mentions two articles in this issue that report that once-daily treatment of fondaparinux initiated in the early post-operative period is more...

  • Acute Budd-Chiari Syndrome Associated with Activated Protein C Resistance During Intravenous Anticoagulant Treatment. Yildiz, B�lent O.; Oran, Bet�l; B�y�kasik, Yahya; Haznedaroglu, Ibrahim C.; �ekirge, Saruhan; Kirazli, Serafettin // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p220 

    The Budd-Chiari syndrome is a rare but serious condition defined as hepatic venous outflow obstruction. This article presents a case of acute Budd-Chiari syndrome in a 43-year-old woman with activated protein C resistance while she was being treated with intravenous heparin infusion for...

  • Inhibition of Factor Xa: A Potential Target for the Development of New Anticoagulants. Alexander, John H.; Singh, Kanwar P. // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p279 

    Anticoagulant therapy plays an important role in the prevention and treatment of pathologic arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa as a target to achieve therapeutic anticoagulation because of its central and ‘upstream’ position...

  • Anticoagulants. Nicholls, Charlotte; Sani, Mojgan // Nursing Older People;Oct2004, Vol. 16 Issue 7, p35 

    This article reports that in a continuing series of drug and therapeutics updates, Charlotte Nicholls and Mojgan Sani consider the enduring role of anticoagulants in the treatment of thromboembolic diseases. Anticoagulants were discovered in 1924 when a new haemorrhagic disorder was discovered...

  • Selecting an anticoagulant for recurrent venous thromboembolism in cancer. Goodin, Susan // American Journal of Health-System Pharmacy;11/15/2005 Supplement 5, Vol. 62, pS10 

    Purpose. The thrombogenicity of newer anticancer agents and the challenges associated with managing cancer patients on warfarin have led to the evaluation of the low-molecular-weight heparins (LMWHs) for primary and secondary prophylaxis in this high-risk patient population. Summary. The first...

  • Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? Zalpour, Ali; Kroll, Michael H.; Afshar-Kharghan, Vahid; Yusuf, SyedWamique; Escalante, Carmen // Advances in Hematology;2011, Vol. 2011, p1 

    The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated....

  • ANTICOAGULANTS.  // Davis's Drug Guide for Nurses, 9th edition;2005, pC10 

    Presents a pharmacologic profile of drugs that treat and prevent thromboembolic disorders. Contraindications; Precautions; Interactions; Overview of patient education.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics